{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:28:28Z","timestamp":1776774508540,"version":"3.51.2"},"reference-count":29,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectived: Daratumumab is an anti-CD38 monoclonal antibody used in the treatment of multiple myeloma. Its use interferes with the indirect antiglobulin test (IAT). Treatment of reagent red blood cells (RBCs) with dithiothreitol (DTT) is one of the most validated techniques to resolve this interference. The objective of this study is to evaluate the rate of alloimmunization in transfused patients receiving daratumumab and the occurrence of hemolytic transfusion reactions. Materials and Methods: We conducted a single-center, retrospective, descriptive analysis of all patients treated with daratumumab at our institution from October 2016 to April 2024. For daratumumab-treated patients requiring RBC transfusions, an IAT with DTT-pretreated RBCs (DTT-IAT) was performed using the automated Orthovision system. Transfusion was administered only with a previous negative DTT-IAT while respecting Rh and Kell phenotyping. We assessed the transfusion profile of our patient cohort, including their rates of alloimmunization before and after daratumumab initiation, as well as the incidence of hemolytic complications. Additionally, a literature review was performed on reported alloimmunization rates in daratumumab-treated patients. Results: Among all patients, 106 received RBC and\/or platelet transfusions after starting daratumumab. Four had known pre-existing alloantibodies. None developed new alloantibodies or experienced hemolytic complications while receiving anti-CD38 therapy. There were four cases of false-positive DTT-IAT due to residual drug interference or technical variability, in which no alloantibodies or adverse transfusion reactions were detected. Conclusions: Patients receiving daratumumab exhibit a low risk of alloimmunization. This may be partly explained by adherence to Rh and Kell phenotyping and daratumumab\u2019s immunosuppressive effects on alloantibody production. These results support the conclusion that an extended red blood cell phenotype or genotype before starting daratumumab could be omitted if a fast and reliable technique for pretransfusion testing (such as automated DTT-IAT) is available 24 h.<\/jats:p>","DOI":"10.3390\/jcm14165754","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:44:21Z","timestamp":1755186261000},"page":"5754","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Absence of Red Blood Cell Alloimmunization in Transfused Patients Receiving Daratumumab: Experience from a Single Center"],"prefix":"10.3390","volume":"14","author":[{"given":"Lara","family":"Eritzpokhoff","sequence":"first","affiliation":[{"name":"Blood Bank and Hematology Department, Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2679-9268","authenticated-orcid":false,"given":"Ernesto","family":"Taleg\u00f3n De La Fuente","sequence":"additional","affiliation":[{"name":"Blood Bank and Hematology Department, Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Carril Barcia","sequence":"additional","affiliation":[{"name":"Blood Bank and Hematology Department, Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-3656","authenticated-orcid":false,"given":"Pedro","family":"Asensi Cant\u00f3","sequence":"additional","affiliation":[{"name":"Blood Bank and Hematology Department, Hospital La Fe, 46026 Valencia, Spain"},{"name":"CIBERONC, Instituto Carlos III, Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Universitario y Polit\u00e9cnico La Fe de la Comunidad Valenciana, Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0679-2905","authenticated-orcid":false,"given":"Ines","family":"G\u00f3mez Segui","sequence":"additional","affiliation":[{"name":"Blood Bank and Hematology Department, Hospital La Fe, 46026 Valencia, Spain"},{"name":"CIBERONC, Instituto Carlos III, Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Universitario y Polit\u00e9cnico La Fe de la Comunidad Valenciana, Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Arnao Herraiz","sequence":"additional","affiliation":[{"name":"Blood Bank and Hematology Department, Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8354-768X","authenticated-orcid":false,"given":"Javier","family":"De La Rubia Comos","sequence":"additional","affiliation":[{"name":"Blood Bank and Hematology Department, Hospital La Fe, 46026 Valencia, Spain"},{"name":"CIBERONC, Instituto Carlos III, Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Universitario y Polit\u00e9cnico La Fe de la Comunidad Valenciana, Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6541-7494","authenticated-orcid":false,"given":"Pilar","family":"Solves Alcaina","sequence":"additional","affiliation":[{"name":"Blood Bank and Hematology Department, Hospital La Fe, 46026 Valencia, Spain"},{"name":"CIBERONC, Instituto Carlos III, Fundaci\u00f3n para la Investigaci\u00f3n del Hospital Universitario y Polit\u00e9cnico La Fe de la Comunidad Valenciana, Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10192","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","article-title":"Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR","volume":"20","author":"Mateos","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/imj.13707","article-title":"Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma","volume":"48","author":"Quach","year":"2018","journal-title":"Intern. Med. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood-2016-11-749432","article-title":"Daratumumab (anti-CD38) induces loss of CD38 on red blood cells","volume":"129","author":"Sullivan","year":"2017","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1111\/trf.16736","article-title":"RBC alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary?","volume":"61","author":"Lee","year":"2021","journal-title":"Transfusion"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.3389\/fimmu.2018.02616","article-title":"Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies","volume":"9","author":"Lancman","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.transci.2018.12.019","article-title":"Validation and cost-effectiveness of an in-house dithiothreitol (DTT)treatment protocol for daratumumab patients in a large tertiary care hospital provides gateway for implementation in smaller community hospitals","volume":"58","author":"Youssef","year":"2019","journal-title":"Transfus. Apher. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102658","DOI":"10.1016\/j.transci.2019.09.011","article-title":"Transfusion management in multiple myeloma patients receiving daratumumab: Experience of a single tertiary care centre","volume":"59","author":"Solves","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/tme.12808","article-title":"Alloimmunisation rate of patients on Daratumumab: A retrospective cohort study of patients in England","volume":"31","author":"Bullock","year":"2021","journal-title":"Transfus. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/trf.14021","article-title":"Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy","volume":"57","author":"Anani","year":"2017","journal-title":"Transfusion"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clml.2017.09.002","article-title":"Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients with Relapsed or Refractory Multiple Myeloma","volume":"18","author":"Chari","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.tracli.2017.12.001","article-title":"Daratumumab: Therapeutic asset, biological trap!","volume":"25","author":"Deneys","year":"2018","journal-title":"Transfus. Clin. Biologique"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bjhh.2017.09.003","article-title":"Transfusion management for patients taking an anti-CD38 monoclonal antibody","volume":"40","author":"Bub","year":"2018","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/trf.15134","article-title":"The impact of Daratumumab on transfusion service costs","volume":"59","author":"Cushing","year":"2019","journal-title":"Transfusion"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/tme.12508","article-title":"Papain-treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti-CD38-based therapies","volume":"29","author":"Cedena","year":"2019","journal-title":"Transfus Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/j.clml.2019.09.254","article-title":"Clinical Characteristics and Transfusion Management of Patients Diagnosed of Multiple Myeloma Receiving Daratumumab: Experience of a Single Centre","volume":"19","author":"Arnao","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/vox.12864","article-title":"Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab","volume":"115","author":"Ye","year":"2020","journal-title":"Vox Sang."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1111\/trf.16687","article-title":"Antibody incidence and red blood cell transfusions in patients on daratumumab","volume":"61","author":"Tauscher","year":"2021","journal-title":"Transfusion"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1111\/trf.16425","article-title":"Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens","volume":"61","author":"Phou","year":"2021","journal-title":"Transfusion"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/trf.17006","article-title":"Efficient neutralization of daratumumab in pretransfusion samples using a novel recombinant monoclonal anti-idiotype antibody","volume":"62","author":"Aung","year":"2022","journal-title":"Transfusion"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103873","DOI":"10.1016\/j.transci.2024.103873","article-title":"Risk of new alloimmunization in patients on anti-CD38 treatment using tube LISS-IAT method","volume":"63","year":"2024","journal-title":"Transfus. Apher. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s12288-024-01763-5","article-title":"A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India","volume":"40","author":"Biswas","year":"2024","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.leukres.2018.06.010","article-title":"Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States","volume":"71","author":"Bell","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chahin, M., Branham, Z., Fox, A., Leurinda, C., and Keruakous, A.R. (2022). Clinical Considerations for Immunoparesis in Multiple Myeloma. Cancers, 14.","DOI":"10.3390\/cancers14092278"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"597959","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity","volume":"11","author":"Wilson","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.15182","article-title":"Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database","volume":"181","author":"Karafin","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/trf.13150","article-title":"When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy","volume":"55","author":"Oostendorp","year":"2015","journal-title":"Transfusion"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/16\/5754\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:27:39Z","timestamp":1760034459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/16\/5754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":29,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14165754"],"URL":"https:\/\/doi.org\/10.3390\/jcm14165754","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}